Company: TAK
Filing Date: 2025-06-27
Form Type: 424B2
Source: 0001628280-25-033198
Chunk: 37

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-27
Form: 424B2
Chunk 37
---
 the public in the DIFC.

<div align='center'>S-27</div>

### EXPERTS
The consolidated financial statements of Takeda Pharmaceutical Company Limited and its subsidiaries as of March 31, 2025 and 2024 and for each of the years in the three-year period ended March 31, 2025, and management’s assessment of the effectiveness of internal control over financial reporting as of March 31, 2025, have been incorporated by reference herein and in the registration statement in reliance upon the reports of KPMG AZSA LLC, an independent registered public accounting firm, incorporated by reference herein, and upon the authority of such firm as experts in accounting and auditing. KPMG AZSA LLC’s address is AZSA Center Building, 1-2, Tsukudo-cho, Shinjuku-ku, Tokyo 162-8551, Japan.

### LEGAL MATTERS
The validity of the Notes and the Guarantee and certain legal matters will be passed upon for us by Sullivan & Cromwell LLP as to matters of United States federal law and New York State law. Certain Japanese legal matters will be passed upon for us by Nishimura & Asahi (Gaikokuho Kyodo Jigyo). The validity of the Notes and the Guarantee will be passed upon for any underwriters, dealers or agents by Simpson Thacher & Bartlett LLP as to matters of United States federal law and New York State law.

### WHERE YOU CAN FIND MORE INFORMATION

#### Available Information
This prospectus supplement is part of a registration statement that we filed with the SEC. The registration statement, including the attached exhibits, contains additional relevant information about Takeda. The rules and regulations of the SEC allow us to omit some of the information included in the registration statement from this prospectus supplement. Takeda is subject to the information requirements of the Exchange Act and, in accordance with the Exchange Act, files annual reports, special reports and other information with the SEC. The SEC maintains an internet site at http://www.sec.gov that contains reports, proxy and information statements and other information about issuers, like Takeda, that file electronically with the SEC. Takeda’s corporate website is http://www.takeda.com.

Takeda is currently exempt from the rules under the Exchange Act that prescribe the furnishing and content of proxy statements, and its officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the